Development of cellular signaling pathway inhibitors as new antivirals against influenza
- PMID: 23603495
- DOI: 10.1016/j.antiviral.2013.04.008
Development of cellular signaling pathway inhibitors as new antivirals against influenza
Abstract
Influenza virus exploits a number of cellular signaling pathways during the course of its replication, rendering them potential targets for new therapeutic interventions. Several preclinical approaches are now focusing on cellular factors or pathways as a means of treating influenza. By targeting host factors, rather than viral mechanisms, these novel therapies may be effective against multiple virus strains and subtypes, and are less likely to elicit viral drug resistance. The most promising candidates are inhibitors of intracellular signaling cascades that are essential for virus replication. This article reviews novel approaches and compounds that target the Raf/MEK/ERK signaling pathway, NF-κB signaling, the PI3K/Akt pathway and the PKC signaling cascade. Although these new antiviral strategies are still in an early phase of preclinical development, results to date suggest they offer a new approach to the treatment of influenza, supplementing direct-acting antiviral drugs.
Copyright © 2013 Elsevier B.V. All rights reserved.
Similar articles
-
Antiviral efficacy against influenza virus and pharmacokinetic analysis of a novel MEK-inhibitor, ATR-002, in cell culture and in the mouse model.Antiviral Res. 2020 Jun;178:104806. doi: 10.1016/j.antiviral.2020.104806. Epub 2020 Apr 15. Antiviral Res. 2020. PMID: 32304723
-
Herbal Medicines with Antiviral Activity Against the Influenza Virus, a Systematic Review.Am J Chin Med. 2018;46(8):1663-1700. doi: 10.1142/S0192415X18500854. Am J Chin Med. 2018. PMID: 30612461
-
Disruption of virus-host cell interactions and cell signaling pathways as an anti-viral approach against influenza virus infections.Biol Chem. 2011 Oct;392(10):837-47. doi: 10.1515/BC.2011.121. Biol Chem. 2011. PMID: 21823902 Review.
-
Inhibition of influenza virus-induced NF-kappaB and Raf/MEK/ERK activation can reduce both virus titers and cytokine expression simultaneously in vitro and in vivo.Antiviral Res. 2011 Oct;92(1):45-56. doi: 10.1016/j.antiviral.2011.05.009. Epub 2011 May 27. Antiviral Res. 2011. PMID: 21641936
-
Targeting cell signalling pathways to fight the flu: towards a paradigm change in anti-influenza therapy.J Antimicrob Chemother. 2009 Jul;64(1):1-4. doi: 10.1093/jac/dkp161. Epub 2009 May 6. J Antimicrob Chemother. 2009. PMID: 19420020 Review.
Cited by
-
Evaluation of the Antiviral Activity of Tabamide A and Its Structural Derivatives against Influenza Virus.Int J Mol Sci. 2023 Dec 9;24(24):17296. doi: 10.3390/ijms242417296. Int J Mol Sci. 2023. PMID: 38139128 Free PMC article.
-
Neuroinflammation in the Evolution of Motor Function in Stroke and Trauma Patients: Treatment and Potential Biomarkers.Curr Issues Mol Biol. 2023 Oct 25;45(11):8552-8585. doi: 10.3390/cimb45110539. Curr Issues Mol Biol. 2023. PMID: 37998716 Free PMC article. Review.
-
MEK inhibitors in cancer treatment: structural insights, regulation, recent advances and future perspectives.RSC Med Chem. 2023 Aug 10;14(10):1837-1857. doi: 10.1039/d3md00145h. eCollection 2023 Oct 18. RSC Med Chem. 2023. PMID: 37859720 Review.
-
Proteomic and genetic analyses of influenza A viruses identify pan-viral host targets.Nat Commun. 2023 Sep 27;14(1):6030. doi: 10.1038/s41467-023-41442-z. Nat Commun. 2023. PMID: 37758692 Free PMC article.
-
FDA-approved Abl/EGFR/PDGFR kinase inhibitors show potent efficacy against pandemic and seasonal influenza A virus infections of human lung explants.iScience. 2023 Feb 28;26(4):106309. doi: 10.1016/j.isci.2023.106309. eCollection 2023 Apr 21. iScience. 2023. PMID: 36968089 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous
